4/5/13 DFH Pharma Inc. (Gaithersburg, Md.) Hetero Group (Hyderabad, India) ND Research and product development agreement to develop next-generation HIV maturation inhibitor drugs Terms were not disclosed 4/4/13 Eddingpharm (Hong Kong) Chiesi Farmaceutici SpA (Parma, Italy) ND Joint venture to establish Chiesi Edding Hong Kong Ltd...C$10 ($9.8) Asset purchase agreement for the exclusive development and commercialization rights in China, Taiwan, Macao and Hong Kong to anti-inflammatory candidate WBI

Hong Kong) GlaxoSmithKline plc (London) ND Collaboration in which to acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer Terms were not disclosed 4/10/13 OPKO Health Inc. (Miami) OAO Pharmsynthez (Russia) ND Partnership to develop and market several OPKO products for sale in Russia and certain other Eastern European countries OPKO acquired about a 10% stake in OAO 4/19/13

Hong Kong and Macau and receive milestone payments from Roche 4/16/13 BIND Therapeutics Inc. (Cambridge, Mass.) AstraZeneca plc (London) $199 Deal to develop and commercialize an Accurin therapeutic based on a molecular targeted kinase inhibitor BIND will get up-front and pre-approval milestone payments totaling $69M and could get more than $130M in regulatory and sales milestones, plus tiered single- to double-digit royalties 4/23/13 BIND Therapeutics Inc. (Cambridge, Mass.) Pfizer Inc. (New

Ltd., of Shanghai, which granted SciClone a license and exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin in intermediate to advanced chronic heart failure

Ablynx NV, of Ghent, Belgium, initiated preclinical development of next-generation anti-IgE Nanobody ALX-0962 in severe allergic asthma. ALX-0962 consists of a potent anti-IgE Nanobody with a dual mode of action – the ability to bind with high affinity to IgE while also displacing receptor-bound IgE – together with a serum albumin binding Nanobody for in vivo plasma half-life extension. BioAlliance Pharma SA, of Paris, reported the International Independent Board of Experts' data and safety

With a sales force established to sell Kalbitor in the U.S., the firm certainly has the capability of marketing on its own in the U.S. Outside the U.S., Dyax has relied on a number of regional deals for Kalbitor, most recently a February agreement giving CVie Therapeutics, of Hong Kong, the right to develop and commercialize the product in China, Hong Kong and Macau

and Zendex Bio Strategy Inc., a Hong Kong private equity investor

ScinoPharm Taiwan Ltd., of Tainan, Taiwan, and Coland Holdings Ltd., of Hong Kong, formed a strategic alliance to develop a series of generic oncological drugs for mainland China

Medigen is taking drug candidate PI-88 for postsurgery-stage liver cancer through a multisite Phase III trial in Taiwan, Korea, Hong Kong and mainland China, with a total of about 500 patients enrolled

Eddingpharm, of Hong Kong, said it inked a joint venture (JV) agreement with Chiesi Farmaceutici SpA, of Parma, Italy, to establish Chiesi Edding Hong Kong Ltd

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research

Hong Kong) ND Expanded development and commercialization deal for Pexa-Vec in China Lee's will expand its commercial rights and development collaboration to cancer types beyond hepatocellular carcinoma, and it will pay Jennerex an up-front payment and milestone payments 2/26/13 Lycera Corp. (Ann Arbor, Mich.) Merck and Co

Hong Kong) GlaxoSmithKline plc (London) ND Collaboration in which to acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer Terms were not disclosed 4/10/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International

Orexo would be entitled to development milestones and royalties 1/28/13 Portola Pharmaceuticals Inc. (South San Francisco) Lee's Pharmaceutical Ltd. (Hong Kong) ND Deal giving Lee's an option to negotiate for commercial rights in China to betrixaban for extended duration venous thromboembolism prophylaxis Lee's will make up-front and continuing payments 1/30/13 Repligen Corp. (Waltham, Mass.) Pfizer Inc. (New York) $70 Exclusive worldwide deal to advance Repligen's spinal muscular atrophy

Eddingpharm, of Hong Kong, said it inked a joint venture (JV) agreement with Chiesi Farmaceutici SpA, of Parma, Italy, to establish Chiesi Edding Hong Kong Ltd

Eddingpharm, of Hong Kong, entered a collaboration with GlaxoSmithKline plc (GSK), of London, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer that was recently approved by the China State Food and Drug Administration

Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau and receive milestone payments from Roche, which will also collaborate on the clinical development and commercialization

Eddingpharm, of Hong Kong, entered a collaboration with GlaxoSmithKline plc (GSK), of London, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer that was recently approved by the China State Food and Drug Administration

Skepticism Prevails Lawrence Wang, managing director of Primavera Capital, Hong Kong, one of the panelists at the meeting, told BioWorld International the underlying reason for the wave of delisting was the market's heightened sense of skepticism of Chinese companies